Favipiravir (CAS 259793-96-9) is a high-purity, pharmaceutical-grade antiviral synthesized via advanced green chemical processes, strictly complying with USP and EP quality standards. Its molecular structure is optimized to selectively inhibit viral RNA-dependent RNA polymerase, a key enzyme for RNA virus replication, enabling broad-spectrum antiviral activity against influenza, coronaviruses, and other RNA pathogens. Produced with minimal impurities (total impurities ≤0.1%) and zero heavy metal residues, each batch undergoes rigorous bioactivity testing to ensure consistent therapeutic performance, making it a trusted raw material for antiviral drug formulation.
This innovative antiviral agent stands out for its rapid onset of action and broad antiviral spectrum, effectively suppressing viral load in infected cells while reducing the risk of transmission. Unlike targeted antiviral drugs that only act on specific viruses, it offers cross-protection against emerging RNA virus variants, providing flexibility for drug development. Its favorable safety profile with minimal adverse reactions supports both short-term treatment and preventive applications, meeting diverse clinical needs.
Favipiravir (CAS 259793-96-9) caters to professional users including pharmaceutical manufacturers developing oral antiviral medications, research institutions exploring RNA virus therapies, and biotech firms addressing emerging infectious diseases. Its proven efficacy, pharmaceutical-grade purity, and compliance with international regulatory standards make it a top choice for buyers prioritizing quality and reliability. Whether for large-scale commercial production or small-batch experimental use, this antiviral delivers unmatched value for global antiviral drug applications.
